Search Results for agency_names:"Justice Department"

The Drug Enforcement Administration (DEA) decided to revoke the DEA Certificate of Registration for Dr. Willard J. Davis, a doctor in Texas, because he lost his state license to practice medicine, which means he can no longer handle controlled substances legally in Texas. The Texas Medical Board suspended Dr. Davis's medical license on May 16, 2024, and it remained suspended at the time of the decision. Since having a valid state medical license is necessary to maintain DEA registration for dispensing controlled substances, his registration was revoked, and any pending applications related to the registration were denied. This decision will be effective starting April 28, 2025.

Restek Corporation has applied to be registered as a bulk manufacturer of certain controlled substances. The application was submitted to the Drug Enforcement Administration on February 19, 2025, and the company plans to produce synthetic versions of substances like Marihuana and Tetrahydrocannabinols for specific purposes. Interested parties can file comments or objections, or request a hearing on this registration by June 17, 2025. All submissions must be made through the Federal eRulemaking Portal.

The Drug Enforcement Administration (DEA) sought to revoke two registrations of Jason Weakley, a registered nurse and advanced practice registered nurse, because he was not authorized to handle controlled substances in Vermont and New Hampshire. Weakley's nursing licenses in both states had expired and remained suspended. He was informed of his right to a hearing but did not request one, leading to a default judgment against him. Consequently, the DEA revoked his registrations, preventing him from handling controlled substances and from renewing or applying for new registrations in these states.

The Federal Bureau of Investigation (FBI), part of the Department of Justice, is planning to send a request to the Office of Management and Budget for approval to collect feedback through the Crime Data Explorer Feedback Survey. This survey aims to gather input from law enforcement, academia, and the general public to enhance the Crime Data Explorer's functionality. The FBI anticipates around 200 responses annually, with each response taking approximately two minutes. This is a continuation of a previously approved information collection, and public comments are invited until March 29, 2021.

The Department of Justice's Antitrust Division plans to extend an existing information collection related to Federal coal leases and is inviting public comments on the proposal. This involves forms ATR-139 and ATR-140, which are used to evaluate the competitive impact of Federal coal lease transactions. About 10 businesses are expected to respond, each taking around two hours, contributing to a total public burden of 20 hours annually. Public feedback is encouraged until March 31, 2025, particularly regarding the necessity, accuracy, utility, and burden of the information collection process.

The Executive Office for Immigration Review (EOIR), which is part of the Department of Justice, is withdrawing two proposed rules regarding immigration proceedings. These rules focused on the procedures for reopening cases after someone has left the U.S. and on defining "good cause" for delaying immigration hearings. EOIR decided to withdraw these proposals as they are reassessing their priorities and believe that further comments and evaluations are needed. This decision maintains the current practices for handling these immigration matters while they consider future actions.

TM Forum, a non-profit organization, submitted notifications to the Attorney General and Federal Trade Commission about changes in its membership. Several companies joined the forum, such as Yettel Hungary and Consumer Cellular, Inc., while others like 2Degrees Mobile, Ltd. and University Belgrade have left. Additionally, some existing members have updated their company names. Membership in the forum remains open, and they plan to notify of any further changes.

Siegfried USA, LLC, located in New Jersey, has submitted an application to become an importer of specific controlled substances, as noted by the Drug Enforcement Administration (DEA). The company plans to import these substances to create active pharmaceutical ingredients for its clients, specifically using Phenylacetone to produce Amphetamine. Comments or objections regarding this application are invited by March 18, 2021, and requests for a hearing can also be made by this date. Final permit approval will align with conditions outlined under the relevant U.S. Code and does not permit the commercial import of drug forms approved or non-approved by the Food and Drug Administration (FDA).

The U.S. Department of Justice and the Drug Enforcement Administration took action against Dr. David Bockoff, resulting in the revocation of his license to prescribe controlled substances. This decision came after a hearing revealed he had violated standards of care in prescribing powerful drugs without proper medical examinations or documentation. The government's investigation showed that between January 2020 and June 2022, he frequently prescribed these drugs in a manner inconsistent with both federal and California laws. Dr. Bockoff did not successfully challenge these findings or take responsibility, leading to the conclusion that his practices were dangerous to public health.

The Drug Enforcement Administration (DEA) has decided to revoke the registration of Dr. Kevin Petersen, meaning he can no longer prescribe or handle controlled substances. This decision came after it was found that his medical license in Nevada, where he practiced, had expired and was then revoked, which automatically made him ineligible to maintain his DEA registration for handling such substances. Dr. Petersen did not contest this action by requesting a hearing, leading the DEA to proceed with its final decision. This order will officially take effect on January 29, 2025.